Atossa Genetics (ATOS) Stock: Gaining On Breast Cancer Update

Atossa Genetics Inc (NASDAQ: ATOS) is headed slightly upward this morning, and for good reason. The company announced a key update in its fight against breast cancer. Of course, this led to excitement among investors, sending the stock toward the top and prompting our partners at Trade Ideas to alert us to the gains. At the moment (10:30), ATOS is trading at $0.53 per share after a gain of 0.92% thus far today.





ATOS Gains On Breast Cancer Update

As mentioned above, Atossa Genetics is having a relatively strong day in the market today after announcing a new program that will be using Chemeric Antigen Recept Therapy, or CAR-T. According to the press release, the company plans to use its proprietary intraductal microcatheter technology to deliver CAR-T cells into the ducts of the breast for the potential targeted treatment of breast cancer/

Essentially, the plan is to use the proprietary system to deliver T-cells that have been genetically modified to attack breast cancer cells. ATOS believes that this method has several advantages. These advantages include:




  • Reduced toxicity achieved by limiting systemic exposure to the T-cells used for the treatment of breast cancer.
  • ATOS also believes that this system will lead to improved efficacy due to direct contact with the target ductal epithelial cells that are undergoing malignant transformation.
  • Lymphatic migration of the CAR-T cells along the same path taken by migrating cancer cells. This has the potential to extend their cytotoxic actions into the regional lymph system, which could limit tumor cell dissemination.

At the moment, ATOS is in the research and development stage and this method has not yet been approved by the FDA or any other regulatory body. As is always the case, pre-clinical and clinical studies demonstrating safety and efficacy among other factors, and regulatory approvals will be required before commercialization. Nonetheless, this is indeed a promising update. In a statement, Steven Quay, MD, PhD, CEO at ATOS, had the following to offer:

We have been encouraged by the promise that CAR-T has shown in other forms of cancer, which is usually delivered systemically. We believe that our proprietary TRAP technology could provide a potentially safer yet effective method to deliver CAR-T… We believe that TRAP CAR-T, as we are calling this novel approach to adaptive T-cell therapy in breast cancer, will provide another approach to breast cancer, and that it may be particularly well-suited for the deadlier forms of breast cancer such as ‘triple negative.’ Now that we have developed a foundational intellectual property position with respect to TRAP CAR-T, we intend to continue research and development through partnership with leading investigators, institutions, and organizations around the world, bringing Atossa’s technology and expertise in TRAP delivery together with experts in our cancer immunology and T-cell biology. Multiple studies in both animals and humans have shown that a number of therapeutics can be delivered by the TRAP, intraductal route…”

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on ATOS. In particular, we’re interested in following the company’s ongoing work to continue fighting various forms of cancer. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!
* indicates required









Add Comment